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CARDIOMYOPLASTY COMBINED WITH IMPLANTATION OF A CARDIOVERTER DEFIBRILLATOR 
Valeri S. Chekanov, MD, PhD, Sanjay Deshpande, MD, and Donald H. Schmidt, MD, Milwaukee, Wis. 
In the United States alone, approximately 2 to 3 million 
patients generally are affected by heart failure, and this 
number is likely to increase. 1 Survival of patients with 
advanced ventricular dysfunction is limited not only by 
progressive pump dysfunction but also by the risk of 
sudden cardiac death. The 1-year mortality risk exceeds 
50% for patients with class IV symptoms. 2 Dynamic 
cardiomyoplasty is emerging as a promising form of 
surgical therapy for patients with advanced ventricular 
dysfunction, but sudden cardiac death remains a major 
factor in decreased long-term survival among patients who 
have undergone cardiomyoplasty. 3 Among the various 
available therapeutic strategies for patients at high risk for 
sudden cardiac death, the implantable cardioverter defi- 
brillator (ICD) has been shown to be effective. Adjunctive 
use of the ICD may therefore provide an optimal outcome 
for patients undergoing cardiomyoplasty. 4 
The following clinical summary describes the course of 
a patient who underwent cardiomyoplasty with concomi- 
tant ICD implantation. We believe that this combined 
procedure may improve survival among cardiomyoplasty 
candidates who are deemed to be at high risk for sudden 
cardiac death. 
Clinical summary. A 65-year-old retired physician with 
advanced ventricular dysfunction related to coronary ar- 
tery disease was evaluated for latissimus dorsi cardiomy- 
oplasty. In the months before evaluation, the patient had 
two episodes of unexplained syncope. He had an out-of- 
hospital cardiac arrest, from which he was successfully 
resuscitated; monomorphic ventricular tachycardia (VT) 
was documented as the initial rhythm. 
The baseline 12-lead electrocardiogram showed sinus 
bradycardia with a first degree atrioventricular block, left 
bundle-branch block, and a rightward axis. During the 
electrophysiology study, sustained monomorphic VT of at 
least three morphologies and rates were easily inducible 
and pace terminable. The patient was started on a regi- 
men of oral amiodarone loading for suppression of VT. 
Cardiac hemodynamic evaluation revealed evidence of 
pulmonary hypertension (right pulmonary artery pressure 
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58/25 mm Hg and mean 36 mm Hg), elevated pulmonary 
capillary wedge pressure (an atrial wave of 28 mm Hg, 
ventricular wave of 42 mm Hg, and mean of 32 mm Hg), 
and reduced cardiac index (2.12 L/min/m2). Coronary 
angiography showed severe three-vessel coronary artery 
disease. The left ventricle was severely hypocontractile, 
with an ejection fraction of 10%. 
Latissimus dorsi cardiomyoplasty was chosen instead of 
heart transplantation because the patient did not have 
end-stage heart failure. Cardiomyoplasty was performed 
through a medial sternotomy and a posterior wrap was 
performed. A Medtronic cardiostimulator (Medtronic, 
Inc., Minneapolis, Minn.) was implanted with the myocar- 
dial and skeletal electrodes placed in the conventional 
manner. The operation was completed without complica- 
tions. 
After satisfactory postoperative r covery, the electro- 
physiologic study was repeated to evaluate the efficacy of 
drug therapy. Monomorphic VT of two hemodynamically 
compromising morphologies remained persistently induc- 
ible. Because of the patient's history of advanced ventric- 
ular dysfunction and cardiac arrest and the electrophysi- 
ologic indications of suppressive drug therapy failure, we 
elected to proceed with the implantation of a cardioverter 
defibrillator for prophylactic management of VT and 
sudden cardiac death. Implantation of an ICD with a 
transvenous lead system was performed 2 weeks after 
cardiomyoplasty. Defibrillation testing was performed 
with step-down energy levels. The lead system used was a 
Medtronic Transvene right ventricular transvenous defi- 
brillation- and rate-sensing electrode with a second defi- 
brillation electrode in the superior vena cava-innominate 
vein junction and a subcutaneous patch placed along the 
left chest wall. A Medtronic pulse generator (model 
7219D) was used in conjunction with this lead system, and 
a defibrillation threshold of 24 J with a biphasic waveform 
was obtained with this configuration. During defibrillation 
testing, the cardiomyoplasty stimulator was temporarily 
programmed to deliver six pulses at the maximum ampli- 
tude to evaluate any potential interaction between the 
cardiomyoplasty device and the ICD. No interaction was 
noted during testing, and all ventricular fibrillation epi- 
sodes were appropriately detected by the ICD. The pa- 
tient had an excellent postoperative r covery after this 
procedure. 
A follow-up electrophysiologic evaluation of the ICD 
and lead system was performed 3 days later. The cardio- 
myoplasty generator was programmed todeliver six pulses 
at maximum amplitude and pulse width during this test- 
ing, and the ICD was programmed at the maximum 
sensitivity to determine whether the ICD sensed any 
signals from the cardiomyoplasty generator. Inappropri- 
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ate sensing was not observed espite these maneuvers, 
and satisfactory defibrillation was obtained at 24 J in a 
biphasic waveform. The cardiomyoplasty generator was 
reprogrammed to its original settings after this procedure, 
and the ICD also remained active. 
The standard Medtronic cardiomyoplasty electrical 
stimulation protocol was started 2 weeks after cardio- 
myoplasty, and the final phase of training was reached 
70 days after the initial cardiomyoplasty operation. 
During the follow-up period, the patient had two 
episodes of VT. Both were detected by the ICD, and 
appropriate therapy was delivered with consequent 
conversion to sinus rhythm. Interrogation and analysis 
of the stored electrograms revealed no interaction 
between the cardiomyoplasty generator and the ICD 
during these clinical events. VT was appropriately 
detected by the ICD without oversensing of the cardio- 
myoplasty generator during both events. 
The patient has continued to report subjective improve- 
ment in functional class. He has had steady progress 
during 1 year of follow-up, although ypothyroidism re- 
sulting from amiodarone therapy has complicated his 
clinical course. Amiodarone therapy was initiated to re- 
duce the frequency of VT, and consequently the number 
of ICD shocks. The patient has had seven ICD shocks for 
monomorphic VT since the initial ICD implantation, with 
five of these shocks occurring before and two after 
initiation of amiodarone therapy. 
Discussion. Survival of patients with advanced ven- 
tricular dysfunction is limited both by progressive pump 
dysfunction and by the risk of sudden cardiac death. 
The principal mechanism of sudden cardiac death in 
this population remains arrhythmia, with VT that de- 
generates into ventricular fibrillation being the most 
common. The development of VT, usually as a result of 
reentry, may be modulated by a variety of triggers, such 
as by alteration in myocardial wall stress from changing 
preload or afterload and by myocardial ischemia. 5 
Additionally, it has been postulated that placement of 
the paced skeletal muscle onto a diseased cardiac 
muscle may create substrates for reentry as a result of 
scar and fibrous tissue development. 
Four groups worldwide have published long-term re- 
sults of clinical dynamic ardiomyoplasty. In each series, 
one of the major causes of late mortality was arrhythmic 
sudden cardiac death. Nine of 38 patients in the Allegheny 
General Hospital, Pittsburgh series died of arrhythmia, 3 
and six of 33 in the Heart Institute, Silo Paulo, Brazil, 
series died suddenly as a result of sudden cardiac death. 6
All of these patients who died suddenly as a result of 
sudden cardiac death were receiving antiarrhythmic ther- 
apy for ventricular arrhythmias or atrial fibrillation. The 
Hospital Broussais, Paris, France, data confirmed eaths 
of 31 of 52 patients from sudden cardiac death. 7The data 
from Bakulev Institute for Cardiovascular Surgery in 
Moscow, Russia, are notable for one death from VT and 
one from sudden cardiac death out of a total of 25 
patients. 8 The overall incidence of sudden cardiac death 
related to VT was 13.5% (20/148) after dynamic ardio- 
myoplasty. 
It is therefore obvious that patients with advanced 
ventricular dysfunction who undergo dynamic ardiomyo- 
plasty remain at high risk for sudden cardiac death. 
Improvement in hemodynamic state and functional class 
does not appear to eliminate this risk. Both primary and 
secondary prevention of sudden cardiac death in this 
population must be addressed. 
In contrast with empirical or electrophysiologically 
guided antiarrhythmic therapy, the ICD appears to be 
associated with the best reduction in sudden cardiac death 
risk in this population. 4 Sudden cardiac death rates at 
5-year follow-up with the ICD have been reported to be 
impressively ow (4.5%). 9 The ICD thus appears to be the 
optimal form of therapy for patients undergoing dynamic 
cardiomyoplasty. 
The timing of ICD implantation with respect to 
dynamic cardiomyoplasty needs to individually deter- 
mined. Cardiomyoplasty may be performed in patients 
who have already undergone ICD implantation. Alter- 
natively, ICD implantation may be performed concom- 
itantly with or soon after the cardiomyoplasty proce- 
dure. In some patients, VT and cardiac arrest have not 
recurred after cardiomyoplasty, perhaps as a result of 
improvement in hemodynamics, ventricular stretch, or 
autonomic imbalance. Implantation of a defibrillator 
should not be deferred in these cases, however, because 
the antiarrhythmic effect of cardiomyoplasty cannot be 
accurately predicted. 
At present, little is known about the potential interac- 
tions between the ICD and cardiomyoplasty systems. It is 
necessary to perform careful intraoperative and postoper- 
ative testing to ensure that the cardiomyoplasty generator 
and the ICD do not interfere with one another. As long as 
care is taken during implantation to ensure that such 
interaction does not occur, long-term follow-up results 
should parallel the results of concomitant ICD and pace- 
maker implantation. In our case, episodes of VT treated 
by the ICD without compromising the operation of the 
cardiomyoplasty generator confirm that there was no 
interaction between the two devices. 
Although dynamic cardiomyoplasty may provide im- 
provement in hemodynamic state and functional class, the 
risk of sudden cardiac death remains a vexing problem. 
Antiarrhythmic drug therapy alone does not appear to 
extend a favorable outcome because of several limitations. 
We anticipate that the ICD combined with dynamic 
cardiomyoplasty will favorably affect survival by reducing 
the risk of arrhythmic death among patients with ad- 
vanced ventricular dysfunction. 
Since the initial writing of this case report, a second 
patient at our institution has undergone cardiomyoplasty 
with concomitant ICD implantation. After the cardiomy- 
oplasty procedure, the patient had symptomatic, nonsus- 
tained VT. This was documented by Holter monitoring 3
months after the cardiomyoplasty operation. Subsequent 
complex electrophysiologic studies documented sustained 
monomorphic VT that was hemodynamically compromis- 
ing and could not be suppressed with procainamide. The 
patient underwent ICD implantation without complica- 
tion. No antiarrhythmic drug therapy was initiated. He has 
had no ICD shocks for the 2-month duration of the 
treatment and has continued to have steady progress. No 
adverse interactions between the two devices were noted 
during testing. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 114, Number 3 
Brief communications 4 9 1 
REFERENCES 
1. Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence 
and mortality rate of congestive heart failure n the United 
States. J Am Coll Cardiol 1991;20:301-6. 
2. Fonorow GC, Chelimsky-Fallick C, Stevenson LW, et al. 
Effect of direct vasodilation vs angiotensin-converting enzyme 
inhibition on mortality in advanced heart failure: the Hy-C 
trial. J Am Coll Cardiol 1992;19:842-50. 
3. Magovern GJ Sr. Paced skeletal muscle for dynamic cardio- 
myoplasty. Ann Thorac Surg 1995;60:1153-4. 
4. Thakur RK, Chow LH, Geraldine GM, et al. Latissimus dorsi 
dynamic cardiomyoplasty: role of combined ICD implantation. 
J Card Surg 1995;10:295-7. 
5. Podrid P J, Fogel RI, Fuchs TT. Ventricular arrhythmia in 
congestive heart failure. Am J Cardiol 1992;69:82G-96G. 
6. Moreira LF, Stolf NA, Bocchi EA, et al. Clinical and left 
ventricular function outcomes up to five years after dynamic 
cardiomyoplasty. J Thorac Cardiovasc Surg 1995;109:353-63. 
7. Carpentier A, Chachques JD, Acar C. Dynamic cardiomyoplasty 
at seven years. J Thorac Cardiovasc Surg 1993;106:42-54. 
8. Chekanov VS, Krakovsky AA, Buslenko NS, et al. Cardiomy- 
oplasty: review of early and late results. Va c Surg 1994;28: 
481-9. 
9. Akhtar M, Avitall B, Jazayeri M, et al. Role of implantable 
cardioverter defibrillator therapy in the management of high- 
risk patients. Circulation 1992;85(suppl 1):1-131. 
CALCIFIED PEDICLED THROMBUS IN THE LEFT VENTRICLE: THE FINE ART OF NATURE 
Carlos Morales, MD, a Jos6 M. Bernal, MD, a Jos6 M. Rabasa, MD, a Francisco Gutidrrez, MD, a Fernando Val, MD, b 
and Jos6 M. Revuelta, MD, a Santander, Spain 
Intracavitary cardiac thrombi are infrequent and usually 
found in patients with concomitant heart disease. These 
thrombi have a rubbery or malleable consistency, and 
calcification is rare. 1 Cases of calcified ball thrombus of 
the fixed type (attached to the atrial wall or septum) have 
occasionally been published. To our knowledge no case of 
calcified pedicled thrombus in the left ventricle has been 
previously reported. 
A 46-year-old man with a recent history of thromboan- 
giitis obliterans and characteristic nodules on the legs was 
found to have a calcified cardiac image on a chest 
roentgenogram while undergoing a work-up for a 6-month 
history of nonspecific discomfort and generalized asthe- 
nia. He was a heavy smoker with moderately elevated 
serum cholesterol levels. He had no symptoms of cardiac 
disease. Doppler echocardiography showed enlargement 
of the left ventricle with a decreased ejection fraction a d 
apical akinesia. An elongated mass was fixed to the apex 
of the left ventricle, moving through the cavity, but no 
mitral valve abnormality was observed. Cardiac catheter- 
ization showed two-vessel disease with significant obstruc- 
tions in the anterior descending and right coronary after- 
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ies. The left ventriculogram showed apical akinesia in the 
area in which a pedicled and elongated mass originated 
(Fig. 1). The operation was performed with the use of 
standard cardiopulmonary b pass. 
With the heart arrested with retrograde cardioplegia, 
the left ventricle was opened through the apex and an 
elongated mass attached to the apical endocardium by 
thin trabeculae was removed. The mass had a smooth, 
hard surface and its color was pearly. The apical opening 
in the left ventricle was repaired with a round Teflon 
patch and autologous pericardium implanted endocardi- 
ally. Coronary artery bypass grafting was done concomi- 
tantly. The resected mass was ovoid and measured 5 cm in 
length by 1.8 cm in diameter in the central area (proximal 
Fig. 1. Left ventriculogram showing the calcified pedi- 
cled mass attached to the apex. A significant lesion is 
present in the proximal anterior descending artery. 
